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ABSTRACT
Objective The strong genetic association between 
HLA-B27 and ankylosing spondylitis has been known for 
over 40 years. HLA-B27 positivity is possibly associated 
with severity of ankylosis. We studied the in vitro and in 
vivo impact of HLA-B27 in models of chondrogenesis and 
osteogenesis.
Methods Different in vitro differentiation systems were 
used to mimic endochondral and direct bone formation. 
ATDC5 cells and primary human periosteum-derived 
cells (hPDCs) were transduced with lentiviral vectors 
expressing HLA-B27 or HLA-B7. These cells and limb 
bud cells (from HLA-B27 transgenic and wild-type (WT) 
mice) were cultured in micromasses. To study direct 
osteogenesis in hPDCs, cells were cultured as monolayers 
and stimulated with osteogenic media. Chondrogenesis 
(COL2, ACAN, COL10) and osteogenesis (OSC, ALP, 
RUNX2) marker expression was studied by quantitative 
RT-PCR. Colorimetric tests were performed to measure 
proteoglycans, mineralization and collagens. Collagen 
antibody-induced arthritis (CAIA) was induced in HLA-B27 
transgenic and WT mice. Clinical scoring and µCTs were 
performed. Statistical analyses were performed by two-
way ANOVA.
Results There was no difference in chondrogenesis 
markers or in colorimetric tests between HLA-B27+ 
and HLA-B7+ micromasses. Expression of osteogenesis 
markers and Alizarin red staining was comparable in 
the HLA-B27+ and the HLA-B7+ hPDCs in monolayers. 
HLA-B27 transgenic mice showed more severe arthritis 
compared with WT mice in the CAIA model. µCT analysis 
showed no increased bone formation in HLA-B27 
transgenic mice.
Conclusion HLA-B27 seems to enhance joint 
inflammation in the CAIA model. We could not document 
a direct effect of HLA-B27 on chondrogenesis or 
osteogenesis.
InTRoduCTIon
Ankylosing spondylitis (AS) is the most 
well-known form of axial spondyloarthritis 
(axSpA), a group of common inflamma-
tory chronic musculoskeletal diseases. Both 
inflammation and structural damage to the 
skeleton determine the long-term outcome 
in patients with AS.1 The former presents as 
osteitis, enthesitis or synovitis and results in 
pain, swelling and associated loss of function. 
The latter is characterised by progressive 
ankylosis of the sacroiliac joints and spine 
and with new cartilage and bone formation 
leading to loss of spinal mobility.2 AS is a para-
digm for complex disorders with both genetic 
and environmental factors playing a role in 
disease onset and progression.3 The relation-
ship between AS and the HLA-B27 gene is 
striking4 5 and remains the strongest associ-
ation between an immune-mediated disease 
and the major histocompatibility complex 
(MHC) known to date.6 However, despite 
40 years of research, it remains unclear how 
HLA-B27 really contributes to AS.7
Radiographic progression in patients with 
AS is highly variable between individual 
patients. Within the patient group with AS, 
the presence of HLA-B27 is hypothesised as 
a risk factor for more severe radiographic 
disease progression although data from large 
studies are somewhat conflicting. A long-term 
study, with a follow-up of 12 years, showed 
more severe radiographic progression in 
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Spondyloarthritis
Key messages
What is already known about this subject?
 ► HLA-B27 is possibly associated with the severity of 
progressive ankylosis in patients with axial SpA.
 ► The exact role of HLA-B27 in the pathogenesis of 
axial SpA is unknown.
What does this study add?
 ► This study demonstrates that HLA-B27 does not play 
a direct role in chondrogenesis  and osteogenesis 
but possibly rather an indirect role by influencing 
inflammation.
How might this impact on clinical practice?
 ► A tight control of inflammation in HLA-B27-positive 
axial SpA patients might prevent progression to 
ankylosis.
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HLA-B27-positive men.8 In addition, accelerated early 
structural disease progression was shown in HLA-B27-pos-
itive AS patients as compared with HLA-B27-negative AS 
patients.9 10 However, in another large study, no associ-
ation between presence of HLA-B27 and radiographic 
progression over 4 years could be demonstrated.11 Within 
the group of patients with axSpA, the proportion of 
HLA-B27+ patients is higher in the AS group as compared 
with the non-radiographic axSpA group.12 The eventual 
impact of HLA-B27 on structural disease progression 
could be explained by more severe inflammation trig-
gering ankylosis in the HLA-B27-positive patients or by a 
direct molecular effect of HLA-B27 on the bone forma-
tion process.
In this study, we investigated the potential direct role of 
HLA-B27 in new cartilage and bone formation in AS by 
using different in vitro and in vivo models.
MATeRIAlS And MeThodS
Cell culture experiments
Lentiviral vectors
Lentiviral vectors expressing GFP-linked HLA-B27 
(pCH-SFFV-B27-ires-GFP) and HLA-B7 (pCH-SFFV-B7-
ires-GFP) were produced by the Leuven Viral Vector Core. 
HLA-B27 and HLA-B7 plasmids were pHR-SIN-BN (HLA-
B27 and HLA-B7 cDNAS were cloned between BamHI 
and NotI sites). After production, functional titres were 
determined for both vectors and were 1.82×108 TU/mL 
for the HLA-B27 viral vector and 1.75×108 TU/mL for the 
HLA-B7 viral vector.
ATDC5 cells
ATDC5 cells were transduced using the HLA-B27-ex-
pressing and HLA-B7-expressing lentiviral vectors. 
ATDC5 cells were cultured at a concentration of 2×105 
cells/mL in a 12-well plate until 90% confluence. Forty 
microlitres of viral vector was subsequently added to the 
cells for 48 hours. After incubation, cells were trypsinized 
and expanded. Transduced ATDC5 cells were cultured as 
3D micromasses for 21 days to stimulate chondrogenesis. 
Micromasses were established and processed as earlier 
described.13 In brief, trypsinized cells were resuspended 
in DMEM medium (Gibco Life Technologies, Ghent, 
Belgium) at a concentration of 2×107 cells/mL. One 
drop of 10 µL of this cell suspension was placed in a well 
of a standard 24-well culture plate. Cells were allowed 
to adhere for 2 hours at 37°C; subsequently, 0.5 mL 
medium was added to each well. For induction of chon-
drogenesis, micromasses were cultured in DMEM/F12 
medium (Gibco Life Technologies) containing 1% anti-
biotic-antimycotic (AB) (Gibco) and 5% FBS (Gibco), 
supplemented with an ITS premix (containing 10 µg/
mL insulin, 5 µg/mL human transferrin and 3×10−8 M 
sodium selenite) (Gibco) and 5 µg/mL human trans-
ferrin (Sigma-Aldrich, Diegem, Belgium) for 2 weeks. 
From day 14 until day 21, a mineralization phase was 
induced using α-MEM medium (Gibco) containing 1% 
AB and 5% FBS and supplemented with ITS premix, 
5 µg/mL human transferrin, 7 mM β-glycerophosphate 
(Sigma-Aldrich) and 50 µg/mL ascorbic acid-2‐phos-
phate (Sigma-Aldrich). Medium was replaced daily. Each 
condition was performed in triplicate.
Human periosteal derived cells
Human periosteal derived cells (hPDCs) were isolated 
and cultured as described previously14 with the approval 
of the ethical committee of UZ Leuven (ML 7861). In 
short, periosteal biopsies (0.5 cm2) were harvested from 
the medial side of the proximal tibia of male and female 
adolescent and adult patients during total knee replace-
ment surgery or distraction osteogenesis. The periosteum 
was stripped from the tibia with a periosteal lifter. 
Specimens were transported in growth medium (GM) 
consisting of high-glucose DMEM supplemented with 1% 
AB and 10% FBS. The biopsies were digested overnight 
at 37°C in 0.2% type IV collagenase (Invitrogen, Merel-
beke, Belgium) in GM. Subsequently, periosteal cells 
were collected by centrifugation and seeded in T25 flask 
in GM. Non-adherent cells were removed after 5 days 
by changing the medium, and the remaining cells were 
expanded in monolayer in GM. On confluence, hPDCs 
were trypsin-released (0.25% trypsin, 1 mM EDTA; Invi-
trogen) and re-plated with a seeding density of 5000 
cells/cm2. From passage 2, hPDCs from different donors 
were pooled to reduce noise from genetic variability. For 
cryopreservation, hPDCs were suspended in DMEM with 
20% FBS and 10% DMSO (Sigma, Bornem, Belgium) 
and stored in liquid nitrogen. Cells were thawed, sub-cul-
tured and subsequently transduced with the HLA-B27 
and HLA-B7 lentiviral vectors. hPDCs were cultured 
at a concentration of 1×105 cells/mL in a 24-well plate 
until 90% confluence. Twenty-five microlitres of viral 
vector was subsequently added to the cells for 48 hours. 
After incubation, cells were trypsinized and expanded. 
Transduced hPDCs were cultured as 3D micromasses 
to study chondrogenesis. Trypsinized cells were resus-
pended in DMEM/F12 medium at a concentration of 
1.5×107 cells/mL. One drop of 10 µL of this cell suspen-
sion was placed in a well of a standard 24-well culture 
plate. Cells were allowed to adhere for 2 hours at 37°C; 
subsequently, 0.5 mL medium was added to each well. 
Standard medium used was DMEM/F12 supplemented 
with 1% AB, 2% FBS and 20 µM Y-27632 Rock1 inhibitor 
(Merck Millipore, Overijse, Belgium). After 48 hours, 
standard medium was replaced by chondrogenic medium 
containing DMEM/F12 medium supplemented with 1% 
AB, 2% FBS, ITS+ premix (Corning, New York, USA), 
100 nM dexamethasone (Sigma-Aldrich), 20 µM Y-27632 
Rock1 inhibitor, 50 µg/mL ascorbic acid-2-phosphate, 
40 µg/mL proline (PeproTech, London, UK) and 10 ng/
mL TGFβ1 (PeproTech). Micromasses were cultured for 
14 days and medium was replaced twice a week. Each 
condition was performed in triplicate.
To study osteogenesis in hPDCs, transduced cells were 
cultured in monolayers for 28 days. Twenty-four hours 
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after seeding, osteogenic medium (DMEM (Gibco) 
supplemented with 1% AB, 10% FBS, 100 nM dexameth-
asone, 50 µg/mL ascorbic acid-2-phosphate and 10 mM 
β-glycerophosphate) was added to the cells. Medium was 
replaced twice a week. Each condition was performed in 
triplicate.
Limb bud cells
HLA-B27 transgenic male C57BL/6 mice (a gift from 
Prof. J. Taurog, Texas, USA)15 were crossed with wild-type 
(WT) C57BL/6 female mice. At day E11.5, the (preg-
nant) mouse was sacrificed. Limb bud cells were derived 
from the HLA-B27 transgenic and WT C57Bl/6 mice 
embryos. After washing the cells with phosphate-buffered 
saline (PBS) (Lonza, Verviers, Belgium) and disinte-
grating them with TripLE (Gibco), maintenance medium 
(40% DMEM, 60% DMEM/F12 supplemented with 1% 
AB and 10% FBS) was added to a final concentration of 
2×107 cells/mL. One drop of 10 µL of this cell suspen-
sion was placed in a well of a standard 24-well culture 
plate. The cells were allowed to adhere for 2 hours at 
37°C; subsequently, 0.5 mL of chondrogenic medium 
(40% DMEM, 60% DMEM/F12 supplemented with 1% 
AB, 10% FBS, 1 mM β-glycerophosphate and 0.25 mM 
ascorbic acid-2-phosphate) was added to each well. 
Medium was changed twice a week.
Flow cytometry
Fluorescence-activating cell sorting (FACS) analysis was 
used to determine surface expression of HLA-B27 on 
ATDC5 cells and hPDCs after transduction. Cells were 
incubated with an anti-HLA-B27 antibody (MAB1285; 
Millipore, Overijse, Belgium) for 30 min. This antibody 
is not specific for HLA-B27 and also binds, although 
less strongly, to the HLA-B7 antigen. Affinity studies by 
Scatchard analysis (provided by the company) showed 
that the antibody has a higher affinity for HLA-B27. 
After intensive washing, cells were resuspended and incu-
bated with secondary antibody (R-PE donkey anti-mouse; 
Jackson Immunoresearch, West Grove, USA) for 20 min. 
Cells were fixed with 1% formaldehyde. Fluorescence 
was assayed using flow cytometry (LSRFortessa SORP, BD 
Biosciences, San Jose, USA); PE was excited by a 561 nm 
laser and emission was collected with a 585/15 bandpass 
filter. Data were analysed using FlowJo v10.1 (FlowJo, 
Ashland, Oregon, USA). Cells were first gated on 
forward scatter and side scatter; subsequently, HLA-B27 
positivity was determined by looking at PE signal versus 
side scatter (ATDC5) or forward scatter (hPDC).
RnA extraction and quantitative RT-PCR
For RNA isolation, samples were digested in Trizol 
(Thermo Fisher Scientific, Ghent, Belgium). RNA 
was isolated using the Nucleospin RNA II kit (Mach-
erey-Nagel, Düren, Germany) according to the 
manufacturer’s protocol. Complementary DNA was 
synthesised from 500 ng of RNA using the RevertAid 
H minus First Strand cDNA synthesis kit (Fermentas, 
St-Leon-Rot, Germany). Gene expression was quantified 
by SYBR green (Fermentas) RT-PCR using the Corbett 
Rotor-Gene 6000 (Corbett Research, Westburg, Leusden, 
The Netherlands). Primers were designed for HLA-B27 
and markers of chondrogenesis (Aggrecan (ACAN), type 
II collagen (COL2), COLX, SOX9 and matrix metallopro-
teinase 13 (MMP13)) and osteogenesis (osteocalcin 
(OCN), osterix (OSX), bone sialoprotein (BSP), alkaline 
phosphatase (ALP) and RUNX2). HPRT1 was used as 
a housekeeping gene. Primer sequences are available on 
request.
Colorimetric tests
After washing with PBS, cells were fixed in 95% ice-cold 
methanol for 30 min at 4°C. After washing intensively with 
distilled water, the cells were stained in either Alcian blue 
(0.1% Alcian Blue 8GX (Sigma-Aldrich) in 0.1 M HCl 
pH 0.2), Safranin O (Klinipath, Olen, Belgium), Alizarin 
red (1% Alizarin Red S (Sigma-Aldrich) in water pH 4.2) 
or Sirius red (0.1% Direct Red 80 (Sigma-Aldrich) in a 
saturated aqueous solution of picric acid). To remove 
unbound staining, cells were washed with distilled water 
until the washing solution remained colourless.
AlP activity assay
Cells were resuspended in Pierce IP Lysis Buffer (Thermo 
Fisher Scientific). Alkaline phosphatase (ALP) activity 
was measured using the BluePhos Microwell Phosphate 
Substrate system (KPL, Gaithersburg, Maryland, USA) 
following the manufacturer’s instructions.
Collagen antibody induced arthritis in mice
Collagen antibody induced arthritis (CAIA) was induced 
in HLA-B27 transgenic and WT C57BL/6 male mice 
(n=10 in each group) using the ArthritoMab Antibody 
Cocktail kit for C57BL/6 (MD Biosciences, Zürich, Swit-
zerland) following the manufacturer’s instructions (with 
approval of the ethical committee UZ Leuven, ML 7770). 
Four microgram of antibody cocktail was injected intra-
peritoneally followed by a boost given after 3 days with 
an intraperitoneal injection of LPS. Clinical scoring was 
performed twice a week. The following scoring system was 
used: severe ankle inflammation: five points, moderate 
ankle inflammation: three points, mild ankle inflamma-
tion: one point, inflammation metatarsophalangeal joint: 
one point, inflammation interphalangeal joint: one point. 
The sum of the scores of the four paws was calculated 
for each time point. µCT scans (SkyScan 1076, Bruker, 
Evere, Belgium) from the hind paws were performed at 
baseline and 3 and 6 weeks after disease induction. The 
volume of the osteophytes at the navicular bone of the 
hind paws was measured by CTAn software (Bruker).
Statistics
GraphPad Prism was used to perform statistical analyses. 
Normality of data distribution was checked by graphs and 
normality tests. Parametric (t-test, ANOVA) or non-para-
metric tests (Mann-Whitney, Kruskal-Wallis) were used 
accordingly. For experiments with multiple variables 
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and/or repeated measurements 2-way ANOVA was used. 
In case of unequal variance, data were log transformed or 
rank transformed. A 2-way ANOVA included assessment 
of time–intervention interaction, time and intervention.
ReSulTS
In vitro experiments
An important part of the new bone formation in AS 
is hypothesised to be endochondral.12 Therefore, we 
used different in vitro systems mimicking this process—
ATDC5 cell micromasses, hPDC micromasses and 
hPDCs in monolayer and limb bud cell micromasses—
to study the potential role of HLA-B27 in new bone 
formation in AS.
HLA-B27 overexpression does not influence endochondral 
bone formation in ATDC5 micromasses
The first model we used was ATDC5 cell micromasses in 
which this cell line undergoes a chondrogenic process 
followed by a mineralization phase when treated with 
chondrogenic and/or mineralization media. Micromasses 
were set up with ATDC5 cells transduced with lentiviral 
vectors expressing HLA-B27 or HLA-B7 (control vector). 
Expression of HLA-B27 and HLA-B7 was successful 
as shown by flow cytometry using an antibody that 
detects both human molecules but with higher affinity 
for HLA-27 (figure 1A). Samples for RNA extraction, 
followed by quantitative RT-PCR, and colorimetric tests 
were taken at days 1, 7, 14 and 21. As shown in figure 2A, 
there was no difference in expression of the cartilage 
markers between the HLA-B27 and the HLA-B7 overex-
pressing micromasses. The experiment was performed 
in triplicate and this was a consistent finding. There was 
also no difference observed in the colorimetric assess-
ment of proteoglycan synthesis (Alcian blue (figure 2B) 
– Safranin O (data not shown)), mineralization (Alizarin 
red) (figure 2B) and collagens (Picrosirius red (data not 
shown)) of the HLA-B27+ and the HLA-B7+ micromasses.
HLA-B27 overexpression does not influence 
chondrogenesis in hPDC micromasses
The second model we used was micromasses set up with 
HLA-B27 and HLA-B7 transduced hPDCs. When treated 
with chondrogenic media, hPDC micromasses are also 
known to undergo chondrogenesis.14 The transduction 
was efficient as shown by FACS, although expression levels 
of HLA-B27 and B7 were lower than seen in the ATDC5 
cells (figure 1B). Samples for RNA extraction, followed 
by quantitative RT-PCR, and Alcian blue staining were 
taken at days 1, 7 and 14. Similar to the observations in 
the ATDC5 micromasses, the expression of chondrogen-
esis markers (ACAN, COL2 and SOX9 as markers of early 
chondrogenesis and COL10 and RUNX2 as markers of late 
chondrogenesis) was not different between the HLA-B27 
and HLA-B7 transduced hPDC micromasses (figure 3A). 
Only the expression of COL2 was significantly lower in 
the HLA-B27+ micromasses compared with the HLA-B7+ 
micromasses (2-way ANOVA, Sidak post hoc p=0,0009) 
at day 14 and the expression of RUNX2 was signifi-
cantly higher in HLA-B27+ micromasses compared with 
HLA-B7+ micromasses (2-way ANOVA, Sidak post hoc 
p=0,0138) at day 1 (figure 3A). There was no differ-
ence seen in the Alcian blue staining of the two types 
of micromasses (figure 3B). We therefore conclude that 
chondrogenesis in hPDC micromasses is not affected by 
presence of HLA-B27.
HLA-B27 overexpression does not influence osteogenesis 
in hPDCs
To study osteogenesis in hPDCs, cells were cultured in 
monolayers for 28 days. hPDCs are known to undergo 
osteogenesis when treated with osteogenic media.14 
Samples for RNA extraction, followed by quantitative 
RT-PCR, ALP activity assay and Alizarin red staining, were 
taken at days 1, 7, 14, 21 and 28. There was no differ-
ence in expression of osteogenesis markers (OCN, ALP 
and RUNX2) between HLA-B27+ and HLA-B7+ hPDCs 
(figure 4A). OSX and BSP were not expressed in this 
set up. The ALP activity assay showed no significant 
difference between HLA-B27+ and HLA-B7+ hPDCs 
(figure 4B). Alizarin red staining did not differ between 
the two conditions (figure 4C). Collectively, we conclude 
that HLA-B27 does not directly influence osteogenesis in 
hPDCs.
HLA-B27 does not influence endochondral bone formation 
in limb bud cell micromasses
The last model we used was HLA-B27 transgenic and 
WT C57BL/6 limb bud micromasses. Limb bud cell 
micromasses are known to undergo endochondral bone 
formation in vitro when treated with chondrogenic 
media.16 Samples for RNA extraction, followed by quan-
titative RT-PCR, and colorimetric tests (Alizarin red and 
Alcian blue) were taken at days 1, 3, 6 and 9. All embryos 
used in this experiment were from the same litter to 
make sure that the limb bud cells were exactly the same 
age as this might be important for the further course 
of differentiation. Chondrogenesis in this model is less 
straight forward than in the other models as shown in 
figure 5. Early chondrogenesis marker expression (Col2 
and Sox9) was decreased from day 1 onwards which 
suggests a rapid acceleration of in vivo initiated chon-
drogenic differentiation from day 1 already, except for 
Acan which expression peaked at day 6 (except one WT 
embryo that peaks at day 9). Col10 expression—as a 
marker of late chondrogenesis—peaked already on 
day 3 for all samples, whereas the other late chondro-
genesis markers (Runx2 and Mmp13) peaked at day 9. 
This course of gene expression was a consistent finding 
in different limb bud micromass experiments (data not 
shown). Altogether, there was no striking difference 
between the course of chondrogenesis gene expression 
in HLA-B27+ and WT micromasses at the molecular level 
(figure 5). The Alizarin red and Alcian blue staining 
were also similar (data not shown).
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Figure 1 Flow cytometry analysis of HLA-B27 and HLA-B7 transduced cells. (A) ATDC5 cells. (B) hPDCs were stained with 
an HLA-B27 antibody and subsequently with a PE-linked secondary antibody. There is a very strong cross-reactivity known 
between HLA-B7-positive cells and the HLA-B27 antibody, as the antibody used binds to both HLA-B27 and HLA-B7. Cells 
were first gated on forward scatter and side scatter; subsequently, HLA-B27/B7 positivity was determined by looking at 
PE signal versus side scatter (ATDC5) or forward scatter (hPDC). The percentage of HLA-B27-positive and HLA-B27-negative 
cells is noted above the plots. (C) Expression of HLA-B27 measured by quantitative RT-PCR, with an HLA-B27-specific primer, 
at the different time point during differentiation of ATDC5 cells, hPDCs during chondrogenesis and hPDCs during osteogenesis. 
FSC, forward-scattered; SSC, side-scattered.
In vivo experiment
For the in vivo part, we induced CAIA in HLA-B27 trans-
genic and WT C57BL/6 mice (n=10 in each group). The 
CAIA model is characterised by the development of syno-
vitis, enthesitis and late-stage new bone formation which 
makes it a valuable model to study AS.
HLA-B27 increases severity of arthritis in the CAIA model
To investigate the influence of HLA-B27 on inflam-
mation in the in vivo CAIA model, clinical scores were 
performed twice a week during 6 weeks. The HLA-B27 
transgenic mice (n=10) showed more severe arthritis of 
the paws compared with the WT mice (n=10 at start, one 
mice died at day 10 and was excluded from analysis). 
The initiation and duration of the inflammation did not 
differ between the two groups, but the intensity of inflam-
mation was significantly higher at days 7, 10 and 14 in the 
group of the HLA-B27 transgenic mice compared with 
the WT mice (2-way ANOVA, Sidak post hoc p=0.0469, 
p<0.0001 and p=0.0056, respectively) (figure 6A). The 
weight of the mice was the same in the two groups 
(figure 6B) which suggests more local inflammation 
without pronounced impact on the general health of the 
mice.
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Figure 2 Endochondral bone formation in HLA-B27 transduced ATDC5 micromasses. (A) Expression of Acan, Col2 and Col10 
measured by quantitative RT-PCR in the HLA-B27 and HLA-B7 ATDC5 micromasses. Statistical analysis was performed by 
two-way ANOVA. p<0.05 was considered as statistically significant. Data points are shown as average and SEM (n=3). (B) 
Alcian blue and Alizarin red staining at the different time points. Acan, Aggrecan; Col2, Collagen type II; Col10, Collagen type X.
Figure 3 Chondrogenesis in HLA-B27 transduced hPDC micromasses. (A) Expression of ACAN, COL2, COL10, RUNX2 and 
SOX9 measured by quantitative RT-PCR in the HLA-B27 and HLA-B7 hPDC micromasses. Statistical analysis was performed 
by two-way ANOVA. p<0.05 was considered as statistically significant. Data points are shown as average and SEM (n=3). (B) 
Alcian blue staining at the different time points. WT, wild-type.
HLA-B27 does not influence new bone formation in the 
CAIA model
In the CAIA model, osteophytes develop in the post-in-
flammatory phase. To study the role of HLA-B27 in new 
bone formation in the in vivo CAIA model, the volume 
of the osteophyte(s) at the navicular bone of the hind 
paws was measured by µCT. In figure 6C, volumes of left 
and right hind paws were summed. All paws except two in 
the HLA-B27 transgenic group and four in the WT group 
developed osteophytes. µCT analysis by CTAn showed no 
increased new bone formation when HLA-B27 transgenic 
mice were compared with WT (figure 6C). There was no 
significant correlation between the peak inflammation 
score and the volume of osteophytes (Pearson correla-
tion, R²=0.1149, p=0.1557) (figure 6D).
dISCuSSIon And ConCluSIon
The link between AS and HLA-B27 has been known 
already for more than 40 years.4 5 Despite this, little is 
known about the possible role of HLA-B27 in new bone 
formation and ankylosis, one of the hallmarks of AS. Most 
research in AS, and particularly the research focusing 
on the role of HLA-B27 in the pathogenesis, focuses on 
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Figure 4 Osteogenesis in monolayer HLA-B27 transduced hPDCs. (A) Expression of OCN, ALP and RUNX2 measured by 
quantitative RT-PCR in the HLA-B27 and HLA-B7 hPDCs. Statistical analysis was performed by two-way ANOVA. p<0.05 was 
considered as statistically significant. (B) ALP activity assay. Data points are shown as average and SEM (n=3). (C) Alizarin red 
staining at the different time points. ALP, alkaline phosphatase; OCN, osteocalcin.
Figure 5 Endochondral bone formation in HLA-B27 and WT limb bud micromasses. Expression of Acan, Col2, Col10, Sox9, 
Runx2 and Mmp13 measured by quantitative RT-PCR in the HLA-B27 and WT limb bud micromasses. Each number represents 
an embryo – green samples are HLA-B27-positive; black samples are WT. WT, wild-type.
inflammation—the second hallmark of AS and leading 
cause of acute signs and symptoms of the disease. We set 
up this study to investigate the possible role of HLA-B27 
in new cartilage and bone formation. The data obtained 
in our study do not show evidence for a direct role for 
HLA-B27 in new cartilage or bone formation. The pres-
ence of HLA-B27 does not seem to affect endochondral 
bone formation in vitro or in vivo, neither in a positive 
nor in a negative way.
Ideally, human samples are used to study disease patho-
genesis as their translational value is much higher than 
samples from in vitro models. As it is very difficult to 
obtain samples from patients with AS, in particular, those 
with early disease—due to ethical concerns as well as due 
to the long time window to develop ankylosis—the use 
of in vitro models was necessary to investigate the role 
of HLA-B27 in new bone formation in this study. As no 
single in vitro model perfectly mimics the process of 
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Figure 6 CAIA model in HLA-B27 transgenic versus WT C57BL/6 mice. (A) Clinical score of mice at different time points. Data 
points are shown as average and SEM. Statistical analysis was performed by two-way ANOVA, Sidak post hoc. p<0.05 was 
considered as statistically significant. (B) Weight of mice at different time points. Data points are shown as average and SEM. 
(C) Measurement of osteophyte volume at the navicular bone of the left and right hind paw at 6 weeks after disease induction. 
Data points are the sum of the volume of the osteophytes at the left and at the right paw from the same mouse. Data points 
are shown as average and SEM. Statistical analysis was performed by unpaired t-test. p<0.05 was considered as statistically 
significant. (D) Correlation between peak inflammation score and osteophyte volume (sum of left and right paw).
human disease, we chose to combine multiple models—
all of them with their own strengths and weaknesses. 
Research from animal models provides strong evidence 
that a large part of the new bone formation in ankylosis 
is due to endochondral bone formation.17 Therefore, 
we chose to use in vitro models mimicking this process. 
Endochondral bone formation is characterised by an 
initial phase of chondrogenesis followed by a terminal 
mineralization phase with attraction of osteoblast 
precursor cells leading to bone replacement.18 The first 
model used is the ATDC5 micromass model. The pres-
ence of HLA-B27 in ATDC5 micromasses does not seem 
to influence the process of endochondral bone differen-
tiation. The ATDC5 micromass system is a well-known in 
vitro model mimicking endochondral bone formation. 
It is a very robust model with an extensive expertise in 
our laboratory. However, the ATDC5 cell line is a mouse 
cell line and might lack expression of important human 
molecules on the one hand and/or express mouse 
molecules on the other hand that could influence the 
behaviour of HLA-B27. One such a molecule is β2 micro-
globulin (β2m), a molecule that binds to the HLA-B27 
heavy chain in the endoplasmic reticulum. Human β2m 
stabilises the HLA-B27 heavy chain when expressed at the 
cell surface. Overexpression of additional human β2m in 
HLA-B27/human β2m transgenic rats promotes arthritis 
and spondylitis,19 suggesting an important role for this 
human molecule in the pathogenesis of AS. Mouse 
β2m, however, could inhibit the possible inflammatory 
and osteogenic properties of HLA-B27 as it is seen that 
HLA-B27 transgenic mice do not show inflammatory 
disease15 20 whereas HLA-B27 expression in a mouse 
β2m-deficient mouse model induces inflammatory 
arthritis of the hind paws and nail changes.21
To overcome this issue, we studied another micromass 
model using human cells, more specifically hPDCs. These 
cells do express human β2m. This model only mimics the 
chondrogenic part of endochondral bone formation. In 
the monolayer experiments, we also tested direct osteo-
genic differentiation. Also in hPDC models, the presence 
of HLA-B27 does not influence new cartilage or bone 
formation. hPDC micromasses show less pronounced 
chondrogenesis than ATDC5 micromasses which is 
reflected in the course and magnitude of chondrogenic 
gene expression. The combination of gene expression 
and colorimetric tests, however, make it a valuable model. 
As endochondral bone formation is an essential process 
in developing long bones, the limb bud micromasses are 
a logic model to study this process in vitro. Remarks for 
the use of this model in our study are the fact that these 
cells are also derived from mice and thus express mouse 
β2m and the fact that gene expression is highly variable 
between different samples. The latter is also the reason 
why gene expression is presented per embryo and is not 
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pooled as average. Despite the limitations of the indi-
vidual models, the strength of this study is the consistent 
finding that in all the used models – either human or 
mouse—the presence of HLA-B27 does not seem to influ-
ence new cartilage and bone formation.
The in vitro models could also be too simplistic and 
miss crucial molecules to mimic the real in vivo setting 
of new cartilage and bone formation. However, this 
rather simple set up was a conscious choice to study the 
direct role of HLA-B27 in chondrogenic/osteogenic cell 
differentiation without influence of possibly interfering 
molecules. We therefore also purposefully chose not to 
trigger cells with inflammatory cytokines. Furthermore, 
consistent with the in vitro findings, the presence of 
HLA-B27 did also not influence new bone formation in 
the in vivo model we used. In this study, we chose the 
CAIA model to study new bone formation in vivo. New 
bone formation, present as osteophytes, occurs in the 
post-inflammatory phase in this model and is present 
in almost every mouse. Intriguingly, there was more 
inflammation seen in the HLA-B27 transgenic animals 
compared with the controls. Bone formation, however, 
did not differ significantly between the groups. This 
finding might be suggestive that HLA-B27 does not play a 
role in new bone formation in AS but that its specific and 
unique properties, including misfolding and cell surface 
dimer expression, may be an additional driving factor in 
different types of inflammation.
There are several plausible explanations for the nega-
tive results of our study. First, it is possible that HLA-B27 
is only necessary to trigger the disease and does not play 
a role in the further development of AS, in particular, in 
those processes that lead to radiographic changes.
Second, it is plausible that HLA-B27 only plays a role 
in the inflammatory part of the AS pathogenesis. In 
the last decade, much research has been focused on 
the link between HLA-B27 and AS. Several interesting 
hypotheses are postulated—like the unfolded protein 
response and the free heavy chain hypotheses7—all 
mainly focusing on inflammation and not on new bone 
formation. None of these hypotheses perfectly fills the 
knowledge gap about the exact role of HLA-B27 in AS. 
Probably, a very complex interaction of all these factors 
may lead to the development of AS in HLA-B27-positive 
individuals. Because inflammation and new bone forma-
tion in AS are supposed to be at least partially coupled 
processes, it is possible that HLA-B27 plays an indirect 
role—by triggering inflammation—in the develop-
ment of new bone in AS rather than a direct role. The 
current paradigm suggests that fatty lesions are gradu-
ally replacing areas of active inflammation in the spine 
and sacroiliac joints. This change in microenvironment 
is permissive for the further evolution towards new 
bone formation and ankylosis, although the suggested 
sequence of inflammation, fat metaplasia and bone 
formation is still debated. As new syndesmophytes can 
also be seen in sites without documentation of prior 
inflammation, it seems that inflammation and new bone 
formation are linked but to a large extent also uncou-
pled processes.22 23 Also in favour of the hypothesis that 
HLA-B27 is indirectly linked to new bone formation is 
the fact that spinal hyperostosis per se, such as seen in 
patients with diffuse idiopathic skeletal hyperostosis, is 
not linked to HLA-B27.
Third, it is possible that the presence of the HLA-B27 
molecule alone is not sufficient to influence new bone 
formation. Maybe a more complex milieu is needed to 
induce new cartilage and bone. A possible contributing 
factor could be human β2m, as discussed above. Also 
cytokines could be the missing link between HLA-B27 
and new bone formation. Another additional factor that 
could be the missing link between HLA-B27 and new bone 
formation is mechanical loading. Mechanical loading 
plays an important role in new bone formation in AS as 
shown by Jacques et al24 who induced CAIA in DBA/1 
mice. Subsequently half of the mice were tail suspended 
for 28 days, to prevent mechanical loading on hind paws, 
and half were kept in normal cages. In tail suspended 
mice, osteophytes were significantly smaller compared 
with control mice.24 There is also a small study showing 
a correlation between the extent of bone pathology and 
presence of HLA-B27 in patients with enthesitis at the 
plantar fascia.25 As biomechanical loading does not cause 
new bone formation in every individual, it is possible that 
presence of HLA-B27 links biomechanical stress to devel-
opment of new bone formation in AS and/or vice versa. 
To further investigate this research question, dynamic in 
vitro models with HLA-B27-positive cells are necessary by 
contrast with the static models used in this study. Recent 
evidence shows that presence of HLA-B27 in humans 
affects the serum levels of key regulators of bone homeo-
stasis, such as DDK1, sclerostin and IHH.26 The fact that 
these altered serum levels were seen in HLA-B27-pos-
itive AS patients as well as in HLA-B27-positive healthy 
individuals also suggests the need of an extra trigger 
to induce the disease. It can currently not be excluded 
that HLA-B27-positive individuals are more prone to an 
enhanced reaction of bone to stress, like inflammation or 
mechanical loading for example.
Finally, it is possible that higher levels of HLA-B27 
expression are needed to influence bone formation. In 
the HLA-B27/human β2m transgenic rats, it is known 
that the degree of susceptibility for spondyloarthritis-like 
lesions correlates with the level of HLA-B27 transgene 
expression at the mRNA and protein levels, as kind of 
a ‘threshold’ effect, where a certain level of HLAB27/
human b2m expression must be achieved to obtain a 
disease phenotype.27 The expression of HLA-B27 in 
patients with AS also appears to be higher compared with 
the expression in HLA-B27-positive healthy controls or 
family members,28 29 with no difference in expression of 
total MHC class I molecules between these groups.28 Only 
in the ATDC5 micromasses was the HLA-B27 expression 
was high, but the molecule’s biology could be functionally 
disturbed by mouse β2m. In the other models—hPDCs, 
limb bud cells and CAIA model—HLA-B27 expression 
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was present in about 50% of the cells, which mimics the 
human heterozygote situation.
In conclusion, the results of our study do not argue for a 
direct role of HLA-B27 on new cartilage and bone forma-
tion in AS. If HLA-B27 plays a role in ankylosis, it will 
probably be an indirect role with HLA-B27 contributing 
to inflammation. Nevertheless, all negative experiments, 
even if confirmed by different approaches, should be 
interpreted with caution and only confirm the absence 
of evidence rather than a clear proof. Future research, 
focusing on the specific working mechanism of HLA-B27 
on the one hand and the exact link between inflamma-
tion and new bone formation on the other, is necessary 
to investigate if HLA-B27 plays an indirect role in new 
bone formation.
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